Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
opioid dependence
Biotech
Indivior expects 'significant' R&D team impact after ph. 2 fail
Indivior ended internal development of an opioid use disorder candidate after a phase 2 trial missed its primary endpoint.
Nick Paul Taylor
Apr 30, 2026 9:43am
AI model designs new treatment candidate for opioid addiction
Apr 6, 2026 3:00pm
Eolas regains opioid use disorder drug abandoned by AstraZeneca
Jul 10, 2025 9:33am
Tris' opioid alternative reduces post-surgery pain in phase 3
Jan 22, 2025 8:30am
Pain relief without opioids' ill effects? New molecules found
Oct 3, 2022 3:55pm
ATAI, DemeRx pursue 'neurochemical reset' for addiction
Jan 24, 2020 9:00am
